title: Statements of the Malaysian Society of Gastroenterology & Hepatology and the National Heart Association of Malaysia task force 2012 working party on the use of antiplatelet therapy and proton pump inhibitors in the prevention of gastrointestinal bleeding.
abstract: The working party statements aim to provide evidence and guidelines to practising doctors on the use of antiplatelet therapy and proton pump inhibitors (PPIs) in patients with cardiovascular risk as well as those at risk of gastrointestinal (GI) bleeding. Balancing the GI and cardiovascular risk and benefits of antiplatelet therapy and PPIs may sometimes pose a significant challenge to doctors. Concomitant use of anti-secretory medications has been shown to reduce the risk of GI bleeding but concerns have been raised on the potential interaction of PPIs and clopidogrel. Many new data have emerged on this topic but some can be confusing and at times controversial. These statements examined the supporting evidence in four main areas: rationale for antiplatelet therapy, risk factors of GI bleeding, PPI-clopidogrel interactions and timing for recommencing antiplatelet therapy after GI bleeding, and made appropriate recommendations.
authors.affiliation: Sunway Medical Centre, Selangor, Malaysia. hucktan@hotmail.com
authors.forename: Huck-Joo
authors.initials: HJ
authors.lastname: Tan
authors.forename: Sanjiv
authors.initials: S
authors.lastname: Mahadeva
authors.forename: Jayaram
authors.initials: J
authors.lastname: Menon
authors.forename: Wai Kiat
authors.initials: WK
authors.lastname: Ng
authors.forename: Imran
authors.initials: I
authors.lastname: Zainal Abidin
authors.forename: Francis Kl
authors.initials: FK
authors.lastname: Chan
authors.forename: Khean-Lee
authors.initials: KL
authors.lastname: Goh
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control; D000077144:Clopidogrel; D004347:Drug Interactions; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D008296:Malaysia; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin